tirzepatide pdf 2025 Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: Results from the Phase 3 SURMOUNT-2 Trial | Diabetes Therapy Frontiers | Efficacy and safety

Starting with smaller amounts allows the human body to adjust gradually

46 JainA.LamarkT.SjottemE.LarsenK

Las cpsulas solo compensan si la comodidad determina que mantengas la pauta

SURMOUNT-1 results In this 72-week obesity trial, participants receiving tirzepatide achieved remarkable weight loss results: 5 mg dose: 85% achieved at least 5% weight reduction, with average weight loss of 15% 10 mg dose: 89% achieved at least 5% weight reduction, with average weight loss of 19% 15 mg dose: 91% achieved at least 5% weight reduction, with average weight loss of 21% These results were achieved with consistent weekly dosing